[HTML][HTML] Advances in siRNA Drug Delivery Strategies for Targeted TNBC Therapy
MA Subhan, VP Torchilin - Bioengineering, 2024 - mdpi.com
Among breast cancers, triple-negative breast cancer (TNBC) has been recognized as the
most aggressive type with a poor prognosis and low survival rate. Targeted therapy for …
most aggressive type with a poor prognosis and low survival rate. Targeted therapy for …
Development of bioconjugate-based delivery systems for nucleic acids
Nucleic acids are a class of drugs that can modulate gene and protein expression by various
mechanisms, namely, RNAi, mRNA degradation by RNase H cleavage, splice modulation …
mechanisms, namely, RNAi, mRNA degradation by RNase H cleavage, splice modulation …
Unveiling the challenges of short non-coding RNAs and their prospects in cancer therapy
LCP Dharshini, AKA Mandal - Journal of Drug Delivery Science and …, 2024 - Elsevier
Short non-coding RNAs (sncRNAs) represent a burgeoning frontier in cancer therapeutics
due to their exquisite gene regulatory abilities. These molecules hold immense potential for …
due to their exquisite gene regulatory abilities. These molecules hold immense potential for …
[HTML][HTML] Elevated MCL1 expression drives esophageal squamous cell carcinoma stemness and induces resistance to radiotherapy
J Chen, G Chen, X Fang, J Sun… - Journal of Thoracic …, 2024 - pmc.ncbi.nlm.nih.gov
Background Esophageal squamous cell carcinoma (ESCC) stands as the sixth most
common cause of cancer-related mortality on a global scale, with a strikingly high proportion …
common cause of cancer-related mortality on a global scale, with a strikingly high proportion …
[HTML][HTML] Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy
Stimulator of interferon genes (STING) is a promising target for potentiating antitumor
immunity, but multiple pharmacological barriers limit the clinical utility, efficacy, and/or safety …
immunity, but multiple pharmacological barriers limit the clinical utility, efficacy, and/or safety …
Lipid-siRNA conjugate accesses perivascular transport and achieves durable knockdown throughout the central nervous system
AG Sorets, KR Schwensen, N Francini, A Kjar… - …, 2024 - pmc.ncbi.nlm.nih.gov
Short-interfering RNA (siRNA) has gained significant interest for treatment of neurological
diseases by providing the capacity to achieve sustained inhibition of nearly any gene target …
diseases by providing the capacity to achieve sustained inhibition of nearly any gene target …
Lipid-siRNA conjugate accesses perivascular transport and achieves durable knockdown throughout the central nervous system
AG Sorets, KR Schwensen, N Francini, A Kjar… - bioRxiv, 2024 - biorxiv.org
Short-interfering RNA (siRNA) has gained significant interest for treatment of neurological
diseases by providing the capacity to achieve sustained inhibition of nearly any gene target …
diseases by providing the capacity to achieve sustained inhibition of nearly any gene target …
Synthesis and characterization of chloroquine-modified albumin-binding siRNA-lipid conjugates for improved intracellular delivery and gene silencing in cancer cells
siRNA therapeutics have considerable potential as molecularly-targeted therapeutics in
malignant disease, but identification of effective delivery strategies that mediate rapid …
malignant disease, but identification of effective delivery strategies that mediate rapid …